Vanda Pharmaceuticals (VNDA) Deferred Taxes (2010 - 2025)

Vanda Pharmaceuticals (VNDA) has 8 years of Deferred Taxes data on file, last reported at $103.2 million in Q4 2025.

• For the quarter ending Q4 2025, Deferred Taxes rose 5491.12% year-over-year to $103.2 million; the trailing twelve-month figure through Mar 2026 stood at $89.2 million (up 735.93% YoY), and the FY2025 full-year result was $81.4 million, up 1356.45% from the prior year.
• Deferred Taxes advanced to $103.2 million in Q4 2025, from -$6.0 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $103.2 million in Q4 2025 to a low of -$8.0 million in Q2 2025.
• A 5-year average of $4.1 million and a median of $85500.0 in 2022 frame the typical range for Deferred Taxes.
• Peak annual rise in Deferred Taxes reached 5491.12% in 2025, while the deepest fall reached 3069.51% in 2025.
• Tracing VNDA's Deferred Taxes over 5 years: stood at $1.3 million in 2021, then sank by 68.24% to $417000.0 in 2022, then plunged by 1894.72% to -$7.5 million in 2023, then surged by 74.43% to -$1.9 million in 2024, then jumped by 5491.12% to $103.2 million in 2025.
• Business Quant data shows VNDA's Deferred Taxes at $103.2 million in Q4 2025, -$6.0 million in Q3 2025, and -$8.0 million in Q2 2025.